Johannes Wesling Klinikum Minden — Clinical Trial Site

50 Registered trials

22 Currently recruiting

Organisation

Johannes Wesling Klinikum Minden

Location

Minden, Germany

Identifier

ORG-100040797

Address

Hans-Nolte-Strasse 1, Haeverstaedt, 32429, Germany

Departments

. . Universitätsklinik für Kinder- und Jugendmedizi
Brustzentrum
DE002: Dermatologie
Department of rheumatology and clinical immunology
Department of rheumatologyand clinical immunology
Dermatologie
Eltern-Kind-Zentrum (ELKI)
Haematologie / Onkologie
Hämatologie / Onkologie
Hämatologie, Onkologie
Hematology
Hematology/ Oncology
HNO
Kinder- und Jugendmedizin
Klinik fuer Rheumatologie und Klinische Immunologie
Klinik für Hämatologie, Onkologie und Palliativmedizin
Klinik für Hämatologie/Onkologie/ Palliativmedizin
Klinik für Nieren- und Hochdruckerkrankungen
Klinik für Rheumatologie und klinische Immunologie
Klinik für Rheumatologie/Klinische Immunologie
NA
Neurologie
Neuroradiologie
Onkologie / Hämatologie
Onkologie, Gerinnungsstörungen und Palliativmedizin
Päd. Hämatologie und Onkologie
Pädiatrische Hämatologie und Onkologie
Pediatric hematology/oncology
Pediatric oncology and hematology
Skin Cancer Center Minden
Skin Cancer Center Minden
Studiensekretariat Rheumatologie, Klinik für Rheumatologie und Klinische Immunologie
Universitätsklinik für Hämatologie, Onkologie, Gerinnungsstörungen und Palliativmedizin
Universitätsklinik für Neurologie und Geriatrie
Universitätsklinikum der RU Bochum
Universitätsklinikum für Hämatologie, Onkologie, Hämostaseologie und Palliativmedizin
University Clinic for Dermatology, Venerology, Allergology, and Phlebology
Zentrum für Innere Medizin
Zentrum für Innere Medizin Klinik für Haematologie und Onkologie

Clinical trials at this site (50)

Search interface

SIOP Ependymoma II: An International Clinical Program for the diagnosis and treatment of children, adolescents and young adults with ependym… Recruiting

2024-512222-28-00 Newly diagnosed with an intracranial or spinal ependymo 10 2015-06-02
A Study of the Efficacy and Safety of JNJ-77242113 in Biologic-naïve Participants with Active Psoriatic Arthritis Ended

2023-509239-19-00 Active Psoriatic Arthritis 5 2025-04-03
A research study to evaluate the efficacy and safety of cenerimod in subjects suffering from systemic lupus erythematosus Ended

2024-515871-37-00 Moderate to severe systemic lupus erythematosus 5 2024-10-24
Determine effectiveness of Anifrolumab In Systemic sclerosis Ended

2023-505976-31-00 Systemic Sclerosis (SSc) presenting with Limited or Dif 5 2023-11-24
A Phase 3 Placebo-controlled Study of Milvexian after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack Ended

2022-501176-26-00 Acute Ischemic Stroke and High-Risk Transient Ischemic 5 2023-08-04
A Study of Dato-DXd in Combination With Durvalumab and Carboplatin for First-line Treatment of Advanced NSCLC Without Actionable Genomic Alt… Ended

2023-505993-14-00 Non-Small Cell Lung Cancer (NSCLC) 5 2023-01-05
A study to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory Eosinophilic … Ended

2023-510019-20-00 Relapsing or refractory Eosinophilic Granulomatosis wit 5 2022-07-13
Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active Psoriatic Arthritis (PsA) who are Naïve to Biologic… Ended

2023-506257-37-00 Active Psoriatic Arthritis 5 2021-10-29
The STARBOARD Study: Phase 3 Study of Encorafenib and Binimetinib Plus Pembrolizumab in BRAF V600E/K Mutation-Positive Metastatic or Unresec… Ended

2024-512038-13-00 Metastatic or unresectable locally advanced BRAF V600E/ 5 2021-09-16
A study to evaluate the benefit and safety of Luspatercept (ACE-536) in adults with myeloproliferative neoplasm-associated myelofibrosis on … Ended

2023-507890-17-00 Anemia associated with myeloproliferative neoplasm (MPN 5 2021-02-22
A study on the efficacy and safety of cisplatin/etoposide and concomitant radiotherapy in combination with durvalumab, an immunotherapy, in … Ended

2024-513433-20-00 Limited Disease Small Cell Lung Cancer 4 2020-12-16
A randomized, controlled, open-label, phase III-trial on Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing abemaciclib combi… Ended

2023-509242-35-00 HR+/HER2- early breast cancer 5 2020-07-23
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell… Ended

2023-503591-25-00 Non-small cell lung cancer 5 2020-06-09
Comparison of Carboplatin and Cisplatin in patients with extracranial malignant germ cell tumours Ended

2023-507582-25-00 Malignant Extracranial Germ Cell Tumours (MGCT) 5 2019-08-02
Treatment for previously untreated patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) with an IDH1 or IDH2 mutatio… Ended

2022-502832-37-00 Acute myeloid leukemia 5 2019-03-01
A Study of LY2784544 in patients with blood cancer Ended

2024-514254-69-00 Myeloproliferative neoplasms (MPNs), myelofibrosis, ess 4 2012-10-22
International multicenter, open-label clinical trial for the treatment of acute myeloid leukemia in children and adolescents Halted

2022-500783-35-00 Acute Myeloid Leukemia 5 2022-12-06
The CALiPSO-1 Study: A Study of CNTY-101, a CD19-targeted CAR iNK Cell Product, in Participants with Refractory B cell-mediated Autoimmune D… Ended

2024-518797-13-00 systemic lupus erythematosus [SLE]/lupus nephritis [LN] 3 2025-07-10
Safety and Efficacy of intra-arterial Tenecteplase for non-complete reperfusion of intracranial occlusion Ended

2022-502878-16-00 Acute ischemic strokes with incomplete reperfusion 5 2025-01-23
A Parallel-group (2-Arm), Randomized, Double-blind, 12-week Trial to Evaluate the Efficacy and Safety of MC2-25 Cream and MC2-25 Vehicle in… Ended

2022-500044-38-01 Chronic Kidney Disease associated Pruritus 4 2023-02-20
Efficacy and Safety of secukinumab in patients with new onset of giant cell arteritis who are in clinical remission Ended

2024-512856-40-00 Giant Cell Arteritis 5 2022-09-21
A Study to Evaluate the Efficacy, Safety and Tolerability of a Single Injection of AC102 into the Middle Ear Compared to Oral Steroid Treatm… Ended

2024-513658-31-00 Idiopathic Sudden Sensorineural Hearing Loss 4 2022-08-08
Phase II Study of Fedratinib and Nivolumab Combination in Patients with Myelofibrosis and Resistance or Suboptimal Response to JAK-inhibitor… Ended

2024-513953-64-00 Primary and secondary Myelofibrosis 4 2022-06-23
Adjuvant Immunotherapy with Nivolumab + Relatlimab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III… Ended

2023-507688-20-00 Participants with completely resected Stage III or Stag 5 2021-12-03